Hormonal · Sub-beat · Market Map
Puberty
The youngest cohort in the Hormonal beat. The market is education- and consumer-led — apps, content, adaptive apparel — with a single clinical-stage therapeutic (Spruce) bridging into the adolescent endocrine population via CAH and PCOS. Capital is sparse and pre-seed by default; brand and distribution are the moat.
5
Companies
$200M
Disclosed funding
1
Clinical / pipeline
4
Commercial
2
Countries
4
Stage buckets
Capital concentration
Where the category sits on the maturity curve
Stage distribution across the indexed cohort. Each bar segment is a company count, ordered from pre-seed to public.
2
1
1
1
Pre-seed2
Seed1
Growth1
Public / Marketed1
The map
Companies by infrastructure lane
Infrastructure lane × stage. Cards ordered by maturity then disclosed funding within each row.
Therapeutics
Digital Health
Directory
All companies — sortable & filterable
| Company | Lane | Stage | HQ | Funding ↓ | Latest | Status |
|---|---|---|---|---|---|---|
Spruce Biosciences Congenital adrenal hyperplasia (CAH – affects puberty onset) and PCOS with adrenal androgen excess | Therapeutics | Public / Marketed | USA (South San Francisco CA) | $200M | N/A | Marketed products pipeline: Phase 3 adult CAH; Phase 2 pediatric CAH; Phase 2 PCOS data at ENDO 2024 |
Luna Teen girl health and puberty education (ages 13–19) | Digital Health | Pre-seed | UK (London) | — | 2023 | Commercial – launched 2024 |
Ove Care Puberty and first period education ages 9–17 | Digital Health | Seed | UK | — | 2024 | Commercial – launched Nov 2024 |
Girlology Puberty education for girls and mothers | Digital Health | Growth | USA | — | N/A | Commercial – long-established |
Cloudstate Puberty-stage girls' adaptive bra and apparel | Wellness & Consumer | Pre-seed | USA (Boston MA) | — | 2025 | Launching 2025 |
5 of 5
Analyst POV
Where the white space is
Education > clinical. All consumer-facing entrants are education + community plays. None are payer-reimbursed. Monetization is product, subscription, or ad-supported.
The therapeutic exception. Spruce Biosciences is the only clinical-stage asset touching this cohort, and it does so by way of CAH — an orphan indication that affects puberty onset. Pediatric endocrinology is otherwise a near-empty lane.
White space. Diagnostic on-ramps for early hormonal dysregulation, payer-validated school-health partnerships, and parent-as-buyer SaaS.
As of 2026-06-12 · 5 companies · The Index
Back to Hormonal